Second protest held over planned Rugby hospital ward closure
More than 400 march through Rugby over a decision about the facility at the Hospital of St Cross.
Related Articles
Transcatheter Repair vs. Surgery for Secondary Mitral Regurgitation | NEJM
Quick Take Video Summary from The New England Journal of Medicine — Transcatheter Repair vs. Surgery for Secondary Mitral Regurgitation
Cole Eye Patients Taking GLP-1 Receptor Agonists for Diabetes Did Not Have Worsening Retinopathy
A retrospective study counters some earlier findings linking GLP-1 receptor agonists with worsening retinopathy in patients with diabetes.
American Heart Association Scientific Session Articles
Explore special articles published online first to coincide with presentations at AHA American Heart Association’s Annual Scientific Session.
Seattle system uses grants to form healthy community partnerships
Virginia Mason Franciscan Health distributed $1.7 million among 24 nonprofit organizations collaborating to better the health of their communities.
An Ethicist Draws the Line on AI as Clinical Decision-Maker
This Medical News article is an interview with Sarah C. Hull, MD, MBE, a cardiologist and clinical ethicist at Yale School of Medicine, about appropriate…
US reports first case of Clade I mpox in California
A person in California has tested positive for the emerging strain, which can cause a more serious illness.
Even a Bit of Exercise Can Lower Your Odds for A-fib
TUESDAY, Nov. 12, 2024 (HealthDay News) — A brisk walk or even housecleaning might help folks at risk lower their odds for the dangerous heart…
Private equity firms upping investment in hospital ASCs
Technology advancements, combined with the promise of quicker stays and improved outcomes relative to hospital visits, are expected to fuel ASC growth.
American Heart Association Scientific Session Articles
Explore special articles published online first to coincide with presentations at AHA American Heart Association’s Annual Scientific Session.
Merck licenses Chinese cancer drug, searching for next Keytruda blockbuster
Merck is licensing a new cancer drug from a Chinese firm, entering a buzzy field of oncology.
